C.R. Bard’s (BCR) Hold Rating Reaffirmed at Jefferies Group
Other equities research analysts have also issued research reports about the company. Evercore ISI initiated coverage on C.R. Bard in a research note on Thursday, September 15th. They issued a buy rating and a $235.00 price target for the company. Citigroup Inc. increased their price target on C.R. Bard from $241.00 to $265.00 and gave the stock a buy rating in a research note on Wednesday, July 27th. Barclays PLC increased their price target on C.R. Bard from $224.00 to $235.00 and gave the stock an equal weight rating in a research note on Wednesday, July 27th. BMO Capital Markets reiterated a hold rating and issued a $240.00 price target on shares of C.R. Bard in a research note on Wednesday, July 27th. Finally, Deutsche Bank AG increased their price target on C.R. Bard from $234.00 to $240.00 and gave the stock a hold rating in a research note on Wednesday, July 27th. Thirteen equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. C.R. Bard presently has a consensus rating of Hold and an average target price of $233.00.
C.R. Bard (NYSE:BCR) traded down 0.35% on Tuesday, reaching $227.80. The company’s stock had a trading volume of 75,306 shares. The firm has a 50-day moving average of $221.30 and a 200-day moving average of $218.86. C.R. Bard has a one year low of $172.21 and a one year high of $239.43. The company has a market capitalization of $16.73 billion, a PE ratio of 52.98 and a beta of 0.57.
C.R. Bard (NYSE:BCR) last issued its quarterly earnings results on Tuesday, July 26th. The company reported $2.54 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.47 by $0.07. C.R. Bard had a return on equity of 48.43% and a net margin of 9.20%. The business earned $931.50 million during the quarter, compared to analyst estimates of $915.22 million. During the same quarter in the prior year, the business posted $2.27 EPS. C.R. Bard’s revenue for the quarter was up 8.3% compared to the same quarter last year. Analysts predict that C.R. Bard will post $10.17 EPS for the current year.
In related news, VP Betty D. Larson sold 4,032 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $225.33, for a total value of $908,530.56. Following the completion of the transaction, the vice president now owns 10,298 shares of the company’s stock, valued at $2,320,448.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Timothy M. Ring sold 110,000 shares of the business’s stock in a transaction that occurred on Monday, September 26th. The stock was sold at an average price of $228.96, for a total transaction of $25,185,600.00. Following the completion of the transaction, the chairman now directly owns 96,030 shares of the company’s stock, valued at approximately $21,987,028.80. The disclosure for this sale can be found here. Insiders own 0.97% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. increased its position in shares of C.R. Bard by 415.1% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the company’s stock worth $104,000 after buying an additional 357 shares during the period. Whittier Trust Co. of Nevada Inc. increased its position in shares of C.R. Bard by 43.7% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 454 shares of the company’s stock worth $107,000 after buying an additional 138 shares during the period. NN Investment Partners Holdings N.V. acquired a new position in shares of C.R. Bard during the first quarter worth approximately $100,000. Acrospire Investment Management LLC acquired a new position in shares of C.R. Bard during the first quarter worth approximately $101,000. Finally, LSV Asset Management acquired a new position in shares of C.R. Bard during the second quarter worth approximately $123,000. 87.90% of the stock is owned by institutional investors.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.
Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.